{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:52:52Z","timestamp":1790707972536,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.cct.2021.106335","type":"journal-article","created":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T09:53:47Z","timestamp":1614506027000},"page":"106335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis"],"prefix":"10.1016","volume":"104","author":[{"given":"Manal F.","family":"Abdelmalek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar D.","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent A.","family":"Neuschwander-Tetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Ehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridhar S.","family":"Tirucherai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George H.","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"Shevell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cct.2021.106335_bb0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cct.2021.106335_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cct.2021.106335_bb0015","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cct.2021.106335_bb0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cct.2021.106335_bb0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cct.2021.106335_bb0030","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: facts and figures","volume":"1","author":"Hallsworth","year":"2019","journal-title":"JHEP Rep."},{"issue":"8","key":"10.1016\/j.cct.2021.106335_bb0035","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14740338.2017.1343299","article-title":"Treatment options for nonalcoholic steatohepatitis - a safety evaluation","volume":"16","author":"Issa","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"7","key":"10.1016\/j.cct.2021.106335_bb0040","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic landscape for NAFLD in 2020","volume":"158","author":"Neuschwander-Tetri","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cct.2021.106335_bb0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tem.2010.11.003","article-title":"FGF21 reloaded: challenges of a rapidly growing field","volume":"22","author":"Kharitonenkov","year":"2011","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.cct.2021.106335_bb0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.semcdb.2015.09.021","article-title":"Metabolic fibroblast growth factors (FGFs): mediators of energy homeostasis","volume":"53","author":"Markan","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.cct.2021.106335_bb0055","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1210\/er.2017-00016","article-title":"Fibroblast growth factor 21-metabolic role in mice and men","volume":"38","author":"Staiger","year":"2017","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.cct.2021.106335_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity"},{"issue":"10165","key":"10.1016\/j.cct.2021.106335_bb0065","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cct.2021.106335_bb0070","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2021.106335_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7397840","article-title":"(13)C methacetin breath test for assessment of microsomal liver function: methodology and clinical application","volume":"2017","author":"Gorowska-Kowolik","year":"2017","journal-title":"Gastroenterol. Res. Pract."},{"issue":"3","key":"10.1016\/j.cct.2021.106335_bb0080","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.21907","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"46","author":"Garcia-Tsao","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cct.2021.106335_bb0085","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/gastro\/gow018","article-title":"Oesophageal and gastric varices: historical aspects, classification and grading: everything in one place","volume":"4","author":"Abby Philips","year":"2016","journal-title":"Gastroenterol. Rep. (Oxf)."},{"issue":"3","key":"10.1016\/j.cct.2021.106335_bb0090","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3748\/wjg.v25.i3.308","article-title":"Elastography-based screening for esophageal varices in patients with advanced chronic liver disease","volume":"25","author":"Paternostro","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cct.2021.106335_bb0095","article-title":"Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design","volume":"89","author":"Anstee","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.cct.2021.106335_bb0100","unstructured":"US Department of Health and Human Services. Immunogenicity Testing of Therapeutic Protein Products - Developing and Validating Assays for Anti-drug Antibody Detection. https:\/\/www.fda.gov\/media\/119788\/download. Updated January 2019. Accessed September 2020."},{"issue":"4","key":"10.1016\/j.cct.2021.106335_bb0105","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.cct.2021.106335_bb0110","series-title":"Immunogenicity of Biopharmaceuticals","first-page":"239","article-title":"Presenting an immunogenicity risk assessment to regulatory agencies","author":"Chamberlain","year":"2008"},{"issue":"2","key":"10.1016\/j.cct.2021.106335_bb0115","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/liv.12700","article-title":"Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C","volume":"35","author":"Nielsen","year":"2015","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.cct.2021.106335_bb0120","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/liv.14390","article-title":"Collagen biology and non-invasive biomarkers of liver fibrosis","volume":"40","author":"Karsdal","year":"2020","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.cct.2021.106335_bb0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cct.2021.106335_bb0130","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop","volume":"61","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cct.2021.106335_bb0135","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?","volume":"156","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cct.2021.106335_bb0140","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","article-title":"Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the Liver Forum","volume":"70","author":"Cheung","year":"2019","journal-title":"Hepatology"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:53:15Z","timestamp":1761555195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714421000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":28,"alternative-id":["S1551714421000719"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2021.106335","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2021.106335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106335"}}